On peptides,
longevity,
and the evidence.
I read the primary literature on peptide pharmacology and longevity science, and I write what the controlled evidence does and doesn't show. Signed. Cited. Not medical advice.
Long-form reference work runs on peptidehackerlab.com. This site is the bylined commentary layer: shorter, more opinionated, anchored on individual trials and review articles when the evidence is worth a take.
Recent commentary
All articles →Tesamorelin and Frailty in Older Adults With HIV: What the TRIUMPH Trial Is Testing
The newly published TRIUMPH protocol describes an already-running, recruiting Phase 2 trial of tesamorelin as an adjunct to exercise. Its central question is functional: can the intervention improve chair stands, walking, strength, and frailty measures beyond exercise alone?
Tirzepatide's Dopamine Question in Alcohol Use Disorder
A new NIAAA-sponsored Phase 1b trial will use PET/MRI to directly measure dopamine receptor availability in people with alcohol use disorder before and after tirzepatide. The preclinical rationale is solid, but the clinical translation question has not been answered for any dual GIP/GLP-1 agonist.
Tirzepatide Muscle Loss Is the Wrongly Framed Question
The recruiting GRAMS trial is not a result. It is a better question. By measuring DXA fat-free mass, thigh MRI muscle quality, and bone turnover markers, NCT07154719 can clarify what the GLP-1 body-composition debate keeps flattening.
Senolytics for the Aging Eye: The Evidence Is Mostly Mice
A new review in Biogerontology places senolytic agents alongside gene editing and stem cells as high-priority interventions for AMD, cataracts, and dry eye. The mechanistic case is solid. The clinical evidence for the eye specifically is almost entirely preclinical, and that gap matters.
What I cover
- GHRH analogs
- Sermorelin, tesamorelin, CJC-1295, and the pulsatile growth-hormone literature.
- GLP-1 receptor agonists
- Semaglutide, tirzepatide, retatrutide — body-composition, hepatic, and cardiovascular endpoints in 2025–2026 trials.
- Tissue-repair peptides
- BPC-157, TB-500, GHK-Cu, and the persistent gap between preclinical and human evidence.
- Mitochondrial and longevity peptides
- MOTS-c, SS-31, NAD+, Epithalon — what the literature claims versus what controlled trials demonstrate.